HIV Infections
Conditions
Keywords
Chronic Hepatitis C, Co-infection, Induction dose, HIV, HIV Infections
Brief summary
The purpose of this study is to compare the early virological response (EVR = undetectable \[ribonucleic acid-hepatitis C virus\] RNA-HCV or a reduction of \> 2 log10) of patients with chronic hepatitis C coinfected with HIV treated with induction doses of peginterferon alpha-2a (40 KD) 270 µg/week and ribavirin 1600 mg/day for 4 weeks, followed by 8 weeks of treatment with peginterferon alpha-2a (40 KD) 180 µg/week and ribavirin 1000-1200 mg/day versus treatment with peginterferon alpha-2a (40 KD) 180 µg/week and ribavirin 1000-1200 mg/day for 12 weeks.
Detailed description
This study seeks to ascertain whether treatment with higher doses of PEGASYS (270 µg/week) and ribavirin (1600 mg/day) for the first four weeks achieves the plasma concentrations of the product in the blood needed to reduce the half-life of the virions and accelerate the elimination thereof. This would bring the viral kinetic curves in coinfected patients closer to the model described for mono-infected HCV patients, probably achieving improved rates of response in week 12 (early virological response) and posterior in week 72 (sustained virological response). Therefore, the patients were randomised to treatment with two different doses, 270 µg and 180 µg of PEGASYS, and 1600 mg and 1000-1200 mg of ribavirin.
Interventions
DRUGPeginterferon alfa-2a, Ribavirin, epoetin-β
Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
DRUGPeginterferon alfa-2a + Ribavirin for 12 weeks
Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
Sponsors
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Germans Trias i Pujol Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Serological evidence of chronic hepatitis C infection in an anti-HCV antibody test * Detectable RNA-HCV plasma level genotype 1 and 4 * ALT serum activity above the upper limit of normality * Chronic liver disease consistent with chronic hepatitis C infection in a biopsy obtained during the two years prior to inclusion in the study * Serological evidence of HIV-1 infection, diagnosed by Enzyme-Linked Immunosorbent Assay (ELISA) and confirmed by Western-blot. * Patients with CD4 cell count \> 200 /µl * Stable status in HIV-1 infection, in the investigator's opinion, in other words, patients that are not expected to progress during the study. * Patients treated with stable anti-retroviral therapy (HAART), which does not include nucleoside analogues, for at least 6 weeks before the baseline assessment * Patients that do not receive HAART therapy * Negative pregnancy test in urine or blood
Exclusion criteria
* Women currently pregnant or in the lactation period. * Patients whose companion is pregnant. * Therapy with interferon (IFN) or ribavirin at any previous time. * Patients with cirrhosis in the hepatic biopsy. * Documented suspicion by ultrasound of hepatocarcinoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with undetectable RNA-HCV | at week 12 after starting treatment |
Secondary
| Measure | Time frame |
|---|---|
| Variations of the levels of RNA-HCV | from baseline until weeks 4, 8, and 12 of the study |
| Percentage of patients with undetectable HCV RNA | in weeks 4 and 8 of the study |
| Levels of ALT | At weeks 4, 8, and 12 |
| Changes in the CD4/CD8 cell count | At 4, 8, and 12 weeks of follow-up |
| Percentage of patients that drop out of the study for adverse effects or intolerance | During the 12 weeks of follow-up |
| Variations in levels of haemoglobin, neutrophil, and platelet count | at 4, 8, and 12 weeks with regard to baseline |
| AIDS-defining events or death | During the 12 weeks of follow-up |
| Percentage of patients that must reduce the dose of peginterferon alpha-2a (40 KD) and ribavirin. | During the 12 weeks of follow-up |
Countries
Spain
Outcome results
None listed